Clinical trials: Psoriasis; Plaque
Psoriasis
Trial to Evaluate Topical C-82 in a Psoriasis Plaque Test
Evaluate the effects of topical C-82 in a psoriasis plaque test.
- Trial name
- NCT02432027
- Testing
- C-82 Topical Gel, 1%, Daivonex cream, Diprosis gel
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- Prism Pharma Co., Ltd.
Psoriasis
A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis
- Trial name
- NCT06701513
- Testing
- Deucravacitinib
- Where
- 48 sites in France, Switzerland
- Volunteers
- 350 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to evaluate the efficacy, safety, and immunogenicity of ABP 654 compared with ustekinumab in participants with moderate to severe plaque psoriasis.
- Trial name
- NCT04607980
- Testing
- ABP 654, Ustekinumab
- Where
- 84 sites in United States, Canada and 6 more
- Volunteers
- 563 people
- Sponsor
- Amgen
Psoriasis Vulgaris
A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis
The primary objective is to demonstrate added benefit of brodalumab versus a selected systemic comparator in treatment of moderate to severe plaque psoriasis in Germany in subjects who have not previously received systemic…
- Trial name
- NCT03331835
- Testing
- Brodalumab, Fumaric acid esters
- Where
- 30 sites in Germany
- Volunteers
- 210 people
- Sponsor
- LEO Pharma
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis
" This study consists of two parts: Part 1 (Dose Escalation): A randomized, double-blind, placebo-controlled phase in which approximately 20 to 30 adult patients with plaque psoriasis will receive the investigational treatment…
- Trial name
- MECAP (NCT07129382)
- Testing
- CS32582 capsule（low dose）, CS32582 capsule（medium dose）, CS32582 capsule（high dose）
- Where
- 11 sites in China
- Volunteers
- 220 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Plaque Psoriasis
Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis
The purpose of this study was to determine whether early intervention with subcutaneous (s.c.) secukinumab 300 mg in patients with new-onset moderate to severe plaque psoriasis may lead to prolonged symptom-free periods by…
- Trial name
- STEPin (NCT03020199)
- Testing
- Secukinumab, nb-UVB
- Where
- 44 sites in Argentina, Bulgaria and 11 more
- Volunteers
- 196 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)
This is a study of the safety and efficacy of ustekinumab (CNTO 1275) in adolescent patients with moderate to severe psoriasis.
- Trial name
- NCT01090427
- Testing
- Ustekinumab - Half-Standard Dosage, Ustekinumab - Standard Dosage
- Where
- 50 sites in Belgium, Canada and 8 more
- Volunteers
- 110 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
The purpose of this study is to compare the safety and efficacy of risankizumab to methotrexate in participants with moderate to severe plaque psoriasis.
- Trial name
- NCT03219437
- Testing
- risankizumab, methotrexate
- Where
- 11 sites in Brazil
- Volunteers
- 104 people
- Sponsor
- AbbVie
Psoriasis
A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis
This was a randomized, double blind, placebo controlled, parallel group study in 129 subjects with moderate to severe psoriasis with a PASI score of at least 10.
- Trial name
- NCT02618616
- Testing
- ZPL-3893787
- Where
- 24 sites in Belgium, Germany and 2 more
- Volunteers
- 129 people
- Sponsor
- Ziarco Pharma Ltd
Moderate to Severe Chronic Plaque-type Psoriasis
Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis
The purpose of this study is to assess secukinumab high dose (every 2 weeks) vs standard dose (every 4 weeks) in heavy body weight subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT03504852
- Testing
- secukinumab 150 mg
- Where
- 67 sites in United States, Canada and 5 more
- Volunteers
- 331 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared with placebo.
- Trial name
- NCT05020249
- Testing
- bimekizumab
- Where
- 9 sites in South Korea
- Volunteers
- 47 people
- Sponsor
- UCB Biopharma SRL
Chronic Plaque Psoriasis
Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 24 weeks by subjects with chronic plaque psoriasis
- Trial name
- DERMIS-OLE (NCT04286607)
- Testing
- Topical roflumilast
- Where
- 85 sites in United States, Canada and 1 more
- Volunteers
- 337 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Plaque Psoriasis
Trial of CF101 to Treat Patients With Psoriasis
Eligible patients with Psoriasis will be treated with CF101 or placebo twice daily for 16 weeks. All subjects will receive open-lable CF101 in weeks 17-32.
- Trial name
- NCT01265667
- Testing
- CF101
- Where
- 18 sites in United States, Bulgaria and 2 more
- Volunteers
- 293 people
- Sponsor
- Can-Fite BioPharma
Plaque Psoriasis
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis
This is a phase 1, open label, single arm study in which ARQ-151 cream 0.3% is applied QD for 2 weeks to adolescent subjects with chronic plaque psoriasis involving at least 10% body surface area (BSA) and adult subjects with…
- Trial name
- MUSE (NCT04279119)
- Testing
- ARQ-151- cream 0.3%
- Where
- 12 sites in United States
- Volunteers
- 26 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Plaque Psoriasis
Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
This is a multiple-center, randomized, double-blind, placebo-controlled Phase IIb study to evaluate the efficacy and safety of AK101, an anti-IL-12/23 p40 antibody, when administered subcutaneously, in subjects with…
- Trial name
- NCT04173637
- Testing
- AK101
- Where
- 2 sites in China
- Volunteers
- 330 people
- Sponsor
- Akeso
Chronic Plaque-type Psoriasis
Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab
The aim of this study was to describe the effect of direct IL-17A inhibition with secukinumab as compared with the selective inhibition of IL-23 with guselkumab (p19 subunit blocker) in controlling inflammation in psoriatic…
- Trial name
- ARROW (NCT03553823)
- Testing
- Skin biopsies
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)
The IMMagine study aims to validate the newly developed CLCI instrument (DermCLCI-p) in moderate to severe psoriasis (PsO) patients, who will be started on Risankizumb (RZB) treatment and will be enrolled into the validation…
- Trial name
- IMMagine (NCT05959070)
- Where
- 16 sites in Belgium, Canada and 1 more
- Volunteers
- 154 people
- Sponsor
- AbbVie
Plaque Psoriasis
Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis
This multicenter, randomised, double-dummy, Fumaderm® and placebo-controlled, parallel-group study will compare the efficacy and safety of 500 mg of FP187 (250 mg twice daily) compared to 720 mg Fumaderm® (240 mg three times…
- Trial name
- NCT01815723
- Testing
- FP187, Dimethyl fumarate
- Where
- Canada
- Sponsor
- Forward-Pharma GmbH
Plaque Psoriasis
Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis
This is a randomized, double-blind, placebo-controlled, multicenter clinical trial in participants with moderate-to-severe plaque psoriasis .
- Trial name
- NCT06278350
- Testing
- D-2570
- Where
- China
- Volunteers
- 161 people
- Sponsor
- InventisBio Co., Ltd
Chronic Plaque Psoriasis
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis
This is a multicenter extension study to assess the long-term safety, tolerability and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis
- Trial name
- BE ABLE 2 (NCT03010527)
- Testing
- Bimekizumab
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 217 people
- Sponsor
- UCB Biopharma SRL